Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial
– 93% efficacy against predominantly circulating Variants of Concern and Variants of Interest– 91% efficacy in high-risk populations– 100% efficacy against variants “not considered Variants of Concern/Interest”– All COVID-19 hospitalizations/death occurred in the placebo group– Company to host investor conference call today at 8:30 am ET Novavax, Inc. (Nasdaq: NVAX), today announced that NVX-CoV2373, its…
